Oblique Therapeutics

Oblique Therapeutics is a private, pre-revenue biotech leveraging its proprietary AbiProt® platform to generate novel antibody therapeutics against historically undruggable targets, primarily in pain and oncology. The company has validated its technology through strategic collaborations with major players like Eli Lilly and a leading animal health company. Led by an experienced team with a strong pharma background, Oblique aims to build a portfolio of assets while monetizing its platform through partnerships.

AbiProt® - A proprietary antibody discovery platform designed to generate precision antibodies against difficult-to-drug targets (e.g., certain GPCRs, ion channels) that are intractable to conventional methods.

Oblique competes in the crowded and highly competitive field of next-generation biotherapeutics, facing off against large-cap biopharma with internal discovery engines and other biotechs developing alternative platforms for difficult targets (e.g., PROTACs, cyclic peptides, other engineered antibodies). Its differentiation hinges on the unique and proven efficacy of the AbiProt® platform.